We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Realm Therapeutics has reported its second midphase flop of the year. The setback threatens to wipe out Realm’s clinical-phase pipeline, leaving the immunology player with just a preclinical acne asset that features the same active ingredient as the faile